In the European pharmaceutical industry, there were 87 M&A deals announced in Q4 2023, worth a total value of $9.2bn, according to GlobalData’s Deals Database. The $6.9bn acquisition of Viatris by Cooper Consumer Health and IQuest Enterprises was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.

Smarter leaders trust GlobalData

In value terms, M&A activity in Europe decreased by 18% in Q4 2023 compared with the previous quarter’s total of $11.2bn and fell by 72% as compared to Q4 2022. Related deal volume decreased by 1% in Q4 2023 versus the previous quarter and was 28% lower than in Q4 2022.

The top-ranked financial advisors supporting these M&A deals in Europe in Q4 2023 were KPMG International Coop; PricewaterhouseCoopers International; Rothschild & Co with 6, 6, 6 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Europe Q4 2023 were CMS Legal Services EEIG; Baker & McKenzie; Cuatrecasas, Goncalves Pereira with 12, 8, 8 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.

This content was updated on 8 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.